Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
28
04
2022
received:
22
02
2022
accepted:
14
05
2022
pubmed:
4
6
2022
medline:
3
9
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
In 2013 and 2014, the development of microcatheters with balloons for the 4-Fr system and new embolization materials provided various options for transarterial chemoembolization (TACE), expanding the range of treatment strategies. At our hospital, balloon-occluded TACE (B-TACE), conventional TACE (C-TACE), and drug-eluting bead TACE (DEB-TACE) have been actively performed for hepatocellular carcinoma (HCC). This study compared the local recurrence-free (LRF) periods of nodules with complete necrosis (TE4) obtained using each treatment method by extracting the nodules evaluated as complete response by the modified Response Evaluation Criteria in Solid Tumors. We performed 580 TACE procedures between June 2013 and April 2019. Among them, 58 HCC nodules in 43 patients, 33 nodules in 30 patients, and 45 nodules in 25 patients were evaluated as having complete necrosis after C-TACE, DEB-TACE, and B-TACE, respectively. The time to local recurrence for each nodule was defined as the LRF period, and the quality of TE4 for each TACE was examined. Factors related to overall survival and the LRF period were determined by univariate and multivariate analyses, and overall survival and the LRF period were analyzed using the Kaplan-Meier method. Multivariate analysis of the LRF period showed that B-TACE was an independent factor. The median LRF periods were 39.3, 13, and 9.1 months for B-TACE, C-TACE, and DEB-TACE, respectively. Moreover, B-TACE had a significantly longer LRF period than C-TACE and DEB-TACE. Conclusion: There was no significant difference between C-TACE and DEB-TACE. The LRF period of nodules with TE4 was the longest with B-TACE, suggesting that B-TACE should be used to achieve a radical cure in patients with HCC.
Identifiants
pubmed: 35656864
doi: 10.1002/hep4.2016
pmc: PMC9426391
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2594-2604Informations de copyright
© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Vasc Interv Radiol. 2019 Mar;30(3):305-313
pubmed: 30713031
Hepatol Res. 2019 Sep;49(9):981-989
pubmed: 31231916
Hepatol Res. 2016 Feb;46(2):209-14
pubmed: 26224032
BMC Gastroenterol. 2021 Feb 3;21(1):51
pubmed: 33535972
Springerplus. 2016 Feb 24;5:157
pubmed: 27026854
Oncology. 2019;96(2):79-86
pubmed: 30293080
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Liver Cancer. 2021 Jul 14;10(5):522-534
pubmed: 34721513
Surgery. 2000 Jun;127(6):603-8
pubmed: 10840353
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Ann Transl Med. 2021 Apr;9(8):714
pubmed: 33987412
Cardiovasc Intervent Radiol. 2021 Dec;44(12):1851-1867
pubmed: 34694454
Cardiovasc Intervent Radiol. 2013 Jun;36(3):706-13
pubmed: 22996589
J Hepatol. 2011 Dec;55(6):1332-8
pubmed: 21703190
Gut. 2020 Aug;69(8):1492-1501
pubmed: 31801872
Hepatology. 2021 Jan;73 Suppl 1:158-191
pubmed: 32430997
Clin Mol Hepatol. 2019 Dec;25(4):344-353
pubmed: 31022779
J Hepatol. 2015 Jun;62(6):1304-10
pubmed: 25637785
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Cardiovasc Intervent Radiol. 2022 Mar;45(3):306-314
pubmed: 35037086
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Cancer. 2010 Jan 15;116(2):393-9
pubmed: 19908259
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Radiology. 1983 Aug;148(2):397-401
pubmed: 6306721
Liver Cancer. 2020 Jun;9(3):245-260
pubmed: 32647629
Cardiovasc Intervent Radiol. 2019 Jun;42(6):853-862
pubmed: 30843093
Hepatol Commun. 2022 Sep;6(9):2594-2604
pubmed: 35656864
Cancer. 2005 Jan 15;103(2):299-306
pubmed: 15578688
Liver Cancer. 2015 Dec;4(4):253-62
pubmed: 26734579
Cancers (Basel). 2021 Jan 05;13(1):
pubmed: 33466496
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Br J Cancer. 2014 Jul 15;111(2):255-64
pubmed: 24937669
Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1325-32
pubmed: 22872074
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
pubmed: 16305721
Cardiovasc Intervent Radiol. 2016 Mar;39(3):359-66
pubmed: 26711804